Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

Mefkure ERAKSOY, Kadriye AGAN, Fikri AK, Omer ANLAR, Belgin Petek BALCI, Cavit BOZ, Yahya CELIK, Seref DEMIRKAYA, Husnu EFENDI, Muhtesem GECIZLIOGLU, Dilek GUNAL, Hulya AYDIN GUNGOR, Nihal ISIK, Egemen IDILMAN, Rana KARABUDAK, Aslı KURNE, Munife NEYAL, Serkan OZAKBAS, Ozgul EKMEKCI OZBAY, Cemal OZCAN, Nese SUBUTAY OZTEKIN, Musa OZTURK, Sabahattin SAIP, Aksel SIVA, Aysun SOYSAL, Ozlem TASKAPILIOGLU, Murat TERZI, Omer Faruk TURAN, Recai TURKOGLU, Nezih YUCEMEN, Ayse Nur YUCEYAR, Yasar ZORLU, Cunay ULKU, Huseyin DIB, Deniz UREN
948 330


Exposure to John Cunningham Virus (JCV) has been associated with Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) patients under specific treatments. In order to assess the identifiable risks of Turkish relapsing-remitting multiple sclerosis (RRMS) patients, the seroprevalence rate of JCV antibodies was investigated and compared with demographic and therapy related factors. Serum samples were collected from 308 RRMS patients at 24 centers, and tested by STRATIFY JCV assay for the presence of anti-JCV antibodies. Also, demographic, disease and treatment data were collected at the same time and were used for analysis of associations with seropositivity. The prevalence of anti-JCV antibodies was observed to be 68.2%, which is higher than most countries. There was a trend in terms of higher seroprevalence of antibodies in older patients, and male patients. There was no association with previous
natalizumab use, but there was a significantly higher seroprevalence in patients who used immunosuppressant therapies (p<0.05). JCV prevalence rate is observed to be
high in Turkish MS patients, therefore it would be beneficial to use this marker as a risk stratification tool in clinical decision making.

J. Exp. Clin. Med., 2014; 31: 31-36


John Cunningham Virus; multiple sclerosis; natalizumab; Turkey

Full Text:



Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.

Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.

Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.

Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).